Florbetapir (18F)
- Generic Name
- Florbetapir (18F)
- Brand Names
- Amyvid
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25FN2O3
- CAS Number
- 956103-76-7
- Unique Ingredient Identifier
- 6W15Z5R0RU
- Background
Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide that plays a key role in Alzheimer's Disease pathogenesis. Marketed as the product Amyvid, florbetapir 18F is indicated for positron emission tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
The radionucleide fluorine-18 was chosen as it has a half life of 110 minutes allowing it to accumulate sufficiently in the brain before undergoing positon emission decay.
- Indication
Florbetapir 18F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
- Associated Conditions
- Alzheimer's Disease (AD)
- Associated Therapies
- -
Entire-body PET Scans for Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Diagnostic Test: Entire-body PET-CT scansDrug: Amyvid radiopharmaceutical
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Brain Health Alliance
- Target Recruit Count
- 20
- Registration Number
- NCT04390009
- Locations
- 🇺🇸
Brain Health Alliance, Ladera Ranch, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.